Dr. Kay Discusses the Role of Acalabrutinib in CLL

Neil E. Kay, MD
Published: Friday, Mar 09, 2018



Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) works the same mechanism as ibrutinib (Imbruvica), but has less off-target effects in terms of enzyme targets, says Kay. This means that the toxicity profile of acalabrutinib may be less in some patients than if they were treated with ibrutinib.

Although effective, the major issue with ibrutinib has been the chronic low-grade toxicities such as arthralgia, diarrhea, hypertension, and rash, are problematic for patients. Kay says that many of these toxicities result in patients having to stop treatment with ibrutinib. Acalabrutinib may be a good alternative for these patients.
SELECTED
LANGUAGE


Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) works the same mechanism as ibrutinib (Imbruvica), but has less off-target effects in terms of enzyme targets, says Kay. This means that the toxicity profile of acalabrutinib may be less in some patients than if they were treated with ibrutinib.

Although effective, the major issue with ibrutinib has been the chronic low-grade toxicities such as arthralgia, diarrhea, hypertension, and rash, are problematic for patients. Kay says that many of these toxicities result in patients having to stop treatment with ibrutinib. Acalabrutinib may be a good alternative for these patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x